Incyte Corporation
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- William J. Meury
- Full Time Employees
- 2,844
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 1801 Augustine Cut-Off Wilmington DE United States 19803
- IPO Date
- Dec 6, 1993
- CIK
- 0000879169
- Website
- incyte.com
- Similar Companies
- Business
- Incyte Corporation (INCY) is a Wilmington, Delaware-based biopharmaceutical company founded in 2002 that discovers, develops, and commercializes proprietary medicines for oncology, inflammation, autoimmunity, and dermatology; it operates globally in North America, Europe, and Asia with over 2,500 employees focused on unmet medical needs. The company markets a diversified portfolio of approved products including Jakafi (ruxolitinib) for myelofibrosis, polycythemia vera, and graft-versus-host disease; Opzelura (ruxolitinib) cream for atopic dermatitis and vitiligo; Pemazyre (pemigatinib) for cholangiocarcinoma and myeloid/lymphoid neoplasms; Monjuvi (tafasitamab-cxix) for relapsed or refractory diffuse large B-cell lymphoma; Tabrecta (capmatinib) for non-small cell lung cancer; Iclusig (ponatinib) for leukemia; and Olumiant (baricitinib) for rheumatoid arthritis and alopecia areata; it also advances a robust pipeline of clinical candidates discovered in-house targeting immunology, hematology-oncology, and inflammatory skin conditions. Recent developments include the 2024 acquisition of Escient Pharmaceuticals for $750 million to add first-in-class oral MRGPRX2 antagonists EP262 for hidradenitis suppurativa, prurigo nodularis, and other pruritic skin diseases and EP547 for pruritus in kidney and liver diseases; FDA approval of Niktimvo (axatilimab-csfr) with partner Syndax Pharmaceuticals in August 2024 for chronic graft-versus-host disease; relocation of over 300 Pennsylvania jobs to expanded downtown Wilmington headquarters by 2026 supporting more than 500 positions; and a 2025 roadmap featuring four potential product launches such as ruxolitinib XR and povorcitinib expansions, four pivotal trial readouts, seven proof-of-concept disclosures, and at least three Phase 3 initiations toward over 10 high-impact launches by 2030.
Company News
Buy, Sell, or Hold? Today's Top Upgrades and Downgrades: Boston Scientific, DoorDash, GE Vernova, Honeywell Aerospace, Incyte.
Incyte To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday
Incyte: Upgrading To Hold After ESMO Closed The Valuation Gap
INCY Q3 Loss Narrower Than Expected, Sales Beat, FY'26 View Raised
Incyte Corporation (INCY) Q3 2026 Earnings Call Transcript
What Incyte (INCY) Said on Its Q3 Earnings Call
Incyte (INCY) Reports Q3 Earnings: What Key Metrics Have to Say
Incyte (INCY) Reports Q3 Loss, Beats Revenue Estimates
Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates
Incyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs Transcript
Incyte Highlights Promising Early Data for '890 and '734 in GI Cancers
Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy
Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Incyte Gears Up to Report Q3 Earnings: Will Results Disappoint?
Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option